{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:45:49Z","timestamp":1790138749513,"version":"4.0.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001837","name":"Eesti Teadusfondi","doi-asserted-by":"publisher","award":["MOBTT49"],"award-info":[{"award-number":["MOBTT49"]}],"id":[{"id":"10.13039\/501100001837","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NTNU Norwegian University of Science and Technology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The viral epidemics and pandemics have stimulated the development of known and the discovery of novel antiviral agents. About a hundred mono- and combination antiviral drugs have been already approved, whereas thousands are in development. Here, we briefly reviewed 7 classes of antiviral agents: neutralizing antibodies, neutralizing recombinant soluble human receptors, antiviral CRISPR\/Cas systems, interferons, antiviral peptides, antiviral nucleic acid polymers, and antiviral small molecules. Interferons and some small molecules alone or in combinations possess broad-spectrum antiviral activity, which could be beneficial for treatment of emerging and re-emerging viral infections<jats:italic>.<\/jats:italic><\/jats:p>","DOI":"10.1007\/s00018-022-04635-1","type":"journal-article","created":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T20:13:19Z","timestamp":1669579999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Seven classes of antiviral agents"],"prefix":"10.1007","volume":"79","author":[{"given":"Aleksandr","family":"Ianevski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzaib","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kraipit","family":"Anunnitipat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentyn","family":"Oksenych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Zusinaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanel","family":"Tenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnar","family":"Bj\u00f8r\u00e5s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7716-6955","authenticated-orcid":false,"given":"Denis E.","family":"Kainov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,27]]},"reference":[{"issue":"1","key":"4635_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","volume":"6","author":"NC Kyriakidis","year":"2021","unstructured":"Kyriakidis NC et al (2021) SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines 6(1):28","journal-title":"NPJ Vaccines"},{"key":"4635_CR2","doi-asserted-by":"publisher","first-page":"205873842110026","DOI":"10.1177\/20587384211002621","volume":"35","author":"S Kausar","year":"2021","unstructured":"Kausar S et al (2021) A review: mechanism of action of antiviral drugs. Int J Immunopathol Pharmacol 35:20587384211002620","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"17","key":"4635_CR3","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1016\/j.jmb.2018.06.024","volume":"430","author":"MS Maginnis","year":"2018","unstructured":"Maginnis MS (2018) Virus-receptor interactions: the key to cellular invasion. J Mol Biol 430(17):2590\u20132611","journal-title":"J Mol Biol"},{"key":"4635_CR4","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.3389\/fimmu.2019.02186","volume":"10","author":"K Bosl","year":"2019","unstructured":"Bosl K et al (2019) Common nodes of virus-host interaction revealed through an integrated network analysis. Front Immunol 10:2186","journal-title":"Front Immunol"},{"key":"4635_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac348","author":"A Ianevski","year":"2022","unstructured":"Ianevski A et al (2022) DrugVirus.info 2.0: an integrative data portal for broad-spectrum antivirals (BSA) and BSA-containing drug combinations (BCCs). Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkac348","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"4635_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100189","volume":"2","author":"JT Ladner","year":"2021","unstructured":"Ladner JT et al (2021) Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. Cell Rep Med 2(1):100189","journal-title":"Cell Rep Med"},{"issue":"6","key":"4635_CR7","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3390\/v12060642","volume":"12","author":"A Ianevski","year":"2020","unstructured":"Ianevski A et al (2020) Potential antiviral options against SARS-CoV-2 infection. Viruses 12(6):642","journal-title":"Viruses"},{"issue":"18","key":"4635_CR8","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1056\/NEJMe2204332","volume":"386","author":"L Estcourt","year":"2022","unstructured":"Estcourt L, Callum J (2022) Convalescent plasma for Covid-19\u2014making sense of the inconsistencies. N Engl J Med 386(18):1753\u20131754","journal-title":"N Engl J Med"},{"key":"4635_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12896-016-0232-6","volume":"16","author":"G Kivi","year":"2016","unstructured":"Kivi G et al (2016) HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species. BMC Biotechnol 16:2","journal-title":"BMC Biotechnol"},{"issue":"10","key":"4635_CR10","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3390\/v12101178","volume":"12","author":"A Ianevski","year":"2020","unstructured":"Ianevski A et al (2020) Identification and tracking of antiviral drug combinations. Viruses 12(10):1178","journal-title":"Viruses"},{"issue":"9","key":"4635_CR11","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41573-022-00495-3","volume":"21","author":"G Pantaleo","year":"2022","unstructured":"Pantaleo G et al (2022) Antibodies to combat viral infections: development strategies and progress. Nat Rev Drug Discov 21(9):676\u2013696","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"4635_CR12","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.3390\/v14081739","volume":"14","author":"X Yang","year":"2022","unstructured":"Yang X et al (2022) Antibody-dependent enhancement: \u201cevil\u201d antibodies favorable for viral infections. Viruses 14(8):1739","journal-title":"Viruses"},{"issue":"3 Suppl 4","key":"4635_CR13","first-page":"25","volume":"22","author":"MS Yip","year":"2016","unstructured":"Yip MS et al (2016) Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS. Hong Kong Med J 22(3 Suppl 4):25\u201331","journal-title":"Hong Kong Med J"},{"issue":"3","key":"4635_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.23","volume":"49","author":"J Weber","year":"2017","unstructured":"Weber J, Peng H, Rader C (2017) From rabbit antibody repertoires to rabbit monoclonal antibodies. Exp Mol Med 49(3):e305","journal-title":"Exp Mol Med"},{"issue":"6","key":"4635_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0268806","volume":"17","author":"K Kangro","year":"2022","unstructured":"Kangro K et al (2022) Bovine colostrum-derived antibodies against SARS-CoV-2 show great potential to serve as prophylactic agents. PLoS ONE 17(6):e0268806","journal-title":"PLoS ONE"},{"issue":"10","key":"4635_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013622","volume":"5","author":"WC Ng","year":"2010","unstructured":"Ng WC et al (2010) Prevention and treatment of influenza with hyperimmune bovine colostrum antibody. PLoS ONE 5(10):e13622","journal-title":"PLoS ONE"},{"key":"4635_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.696003","volume":"12","author":"L Lee","year":"2021","unstructured":"Lee L et al (2021) Immunoglobulin Y for potential diagnostic and therapeutic applications in infectious diseases. Front Immunol 12:696003","journal-title":"Front Immunol"},{"issue":"10","key":"4635_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v14102121","volume":"14","author":"E Ravlo","year":"2022","unstructured":"Ravlo E et al (2022) Antiviral immunoglobulins of chicken egg yolk for potential prevention of SARS-CoV-2 infection. Viruses 14(10):1\u201310","journal-title":"Viruses"},{"key":"4635_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.761250","volume":"12","author":"B Vanhove","year":"2021","unstructured":"Vanhove B et al (2021) XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants. Front Immunol 12:761250","journal-title":"Front Immunol"},{"issue":"4","key":"4635_CR20","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","volume":"181","author":"V Monteil","year":"2020","unstructured":"Monteil V et al (2020) Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181(4):905-913 e7","journal-title":"Cell"},{"issue":"2","key":"4635_CR21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1128\/CMR.8.2.293","volume":"8","author":"LC Norkin","year":"1995","unstructured":"Norkin LC (1995) Virus receptors: implications for pathogenesis and the design of antiviral agents. Clin Microbiol Rev 8(2):293\u2013315","journal-title":"Clin Microbiol Rev"},{"issue":"5962","key":"4635_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1126\/science.1179555","volume":"327","author":"P Horvath","year":"2010","unstructured":"Horvath P, Barrangou R (2010) CRISPR\/Cas, the immune system of bacteria and archaea. Science 327(5962):167\u2013170","journal-title":"Science"},{"key":"4635_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fgeed.2021.745559","volume":"3","author":"HJE Baddeley","year":"2021","unstructured":"Baddeley HJE, Isalan M (2021) The application of CRISPR\/Cas systems for antiviral therapy. Front Genome Ed 3:745559","journal-title":"Front Genome Ed"},{"key":"4635_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175173","volume":"931","author":"R Jena","year":"2022","unstructured":"Jena R et al (2022) Treatment strategies for HIV infection with emphasis on role of CRISPR\/Cas9 gene: Success so far and road ahead. Eur J Pharmacol 931:175173","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"4635_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005701","volume":"12","author":"FR van Diemen","year":"2016","unstructured":"van Diemen FR et al (2016) CRISPR\/Cas9-mediated genome editing of herpesviruses limits productive and latent infections. PLoS Pathog 12(6):e1005701","journal-title":"PLoS Pathog"},{"issue":"5","key":"4635_CR26","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.molcel.2019.09.013","volume":"76","author":"CA Freije","year":"2019","unstructured":"Freije CA et al (2019) Programmable inhibition and detection of RNA viruses using Cas13. Mol Cell 76(5):826-837 e11","journal-title":"Mol Cell"},{"issue":"1","key":"4635_CR27","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1038\/s41467-021-24577-9","volume":"12","author":"M Fareh","year":"2021","unstructured":"Fareh M et al (2021) Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance. Nat Commun 12(1):4270","journal-title":"Nat Commun"},{"key":"4635_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.antiviral.2018.05.007","volume":"155","author":"HS Li","year":"2018","unstructured":"Li HS et al (2018) Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model. Antiviral Res 155:89\u201396","journal-title":"Antiviral Res"},{"issue":"1","key":"4635_CR29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/imr.13113","volume":"309","author":"C Chiale","year":"2022","unstructured":"Chiale C, Greene TT, Zuniga EI (2022) Interferon induction, evasion, and paradoxical roles during SARS-CoV-2 infection. Immunol Rev 309(1):12\u201324","journal-title":"Immunol Rev"},{"issue":"3","key":"4635_CR30","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s40121-022-00633-9","volume":"11","author":"D Jhuti","year":"2022","unstructured":"Jhuti D et al (2022) Interferon treatments for SARS-CoV-2: challenges and opportunities. Infect Dis Ther 11(3):953\u2013972","journal-title":"Infect Dis Ther"},{"issue":"8","key":"4635_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/v9080223","volume":"9","author":"JM Shim","year":"2017","unstructured":"Shim JM et al (2017) Influenza virus infection, interferon response, viral counter-response, and apoptosis. Viruses 9(8):223","journal-title":"Viruses"},{"issue":"18","key":"4635_CR32","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1007\/s00018-019-03138-w","volume":"76","author":"LCP Vilas Boas","year":"2019","unstructured":"Vilas Boas LCP et al (2019) Antiviral peptides as promising therapeutic drugs. Cell Mol Life Sci 76(18):3525\u20133542","journal-title":"Cell Mol Life Sci"},{"issue":"Database issue","key":"4635_CR33","doi-asserted-by":"publisher","first-page":"D1147","DOI":"10.1093\/nar\/gkt1191","volume":"42","author":"A Qureshi","year":"2014","unstructured":"Qureshi A et al (2014) AVPdb: a database of experimentally validated antiviral peptides targeting medically important viruses. Nucleic Acids Res 42(Database issue):D1147\u2013D1153","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"4635_CR34","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.3390\/polym14091634","volume":"14","author":"A Akbari","year":"2022","unstructured":"Akbari A et al (2022) Antiviral polymers: a review. Polymers (Basel) 14(9):1634","journal-title":"Polymers (Basel)"},{"key":"4635_CR35","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.3389\/fmicb.2018.02151","volume":"9","author":"A Levanova","year":"2018","unstructured":"Levanova A, Poranen MM (2018) RNA interference as a prospective tool for the control of human viral infections. Front Microbiol 9:2151","journal-title":"Front Microbiol"},{"key":"4635_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.coi.2018.06.010","volume":"54","author":"SW Ding","year":"2018","unstructured":"Ding SW et al (2018) Antiviral RNA interference in mammals. Curr Opin Immunol 54:109\u2013114","journal-title":"Curr Opin Immunol"},{"issue":"12","key":"4635_CR37","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.3390\/v12121434","volume":"12","author":"K Kalke","year":"2020","unstructured":"Kalke K et al (2020) Herpes simplex virus type 1 clinical isolates respond to UL29-targeted siRNA swarm treatment independent of their acyclovir sensitivity. Viruses 12(12):1434","journal-title":"Viruses"},{"issue":"7","key":"4635_CR38","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.3390\/v13071386","volume":"13","author":"L van de Sand","year":"2021","unstructured":"van de Sand L et al (2021) Antiviral active compounds derived from natural sources against herpes simplex viruses. Viruses 13(7):1386","journal-title":"Viruses"},{"issue":"21","key":"4635_CR39","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.3390\/molecules25214878","volume":"25","author":"S Mohan","year":"2020","unstructured":"Mohan S et al (2020) Bioactive natural antivirals: an updated review of the available plants and isolated molecules. Molecules 25(21):4878","journal-title":"Molecules"},{"issue":"17","key":"4635_CR40","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.2174\/1389450122666210215112150","volume":"22","author":"CB Apaydin","year":"2021","unstructured":"Apaydin CB, Cinar G, Cihan-Ustundag G (2021) Small-molecule antiviral agents in ongoing clinical trials for COVID-19. Curr Drug Targets 22(17):1986\u20132005","journal-title":"Curr Drug Targets"},{"key":"4635_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.267","volume":"4","author":"L Kakkola","year":"2013","unstructured":"Kakkola L et al (2013) Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice. Cell Death Dis 4:e742","journal-title":"Cell Death Dis"},{"issue":"10","key":"4635_CR42","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/v9100271","volume":"9","author":"D Bulanova","year":"2017","unstructured":"Bulanova D et al (2017) Antiviral properties of chemical inhibitors of cellular anti-apoptotic Bcl-2 proteins. Viruses 9(10):271","journal-title":"Viruses"},{"issue":"6","key":"4635_CR43","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.3390\/cancers12061694","volume":"12","author":"A Ianevski","year":"2020","unstructured":"Ianevski A et al (2020) Chemical, physical and biological triggers of evolutionary conserved Bcl-xL-mediated apoptosis. Cancers (Basel) 12(6):1694","journal-title":"Cancers (Basel)"},{"issue":"4","key":"4635_CR44","first-page":"102","volume":"13","author":"N Mohammad Zadeh","year":"2021","unstructured":"Mohammad Zadeh N et al (2021) Mechanism and adverse effects of COVID-19 drugs: a basic review. Int J Physiol Pathophysiol Pharmacol 13(4):102\u2013109","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"4635_CR45","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ijid.2020.02.018","volume":"93","author":"PI Andersen","year":"2020","unstructured":"Andersen PI et al (2020) Discovery and development of safe-in-man broad-spectrum antiviral agents. Int J Infect Dis 93:268\u2013276","journal-title":"Int J Infect Dis"},{"issue":"6","key":"4635_CR46","doi-asserted-by":"publisher","first-page":"e0334721","DOI":"10.1128\/mbio.03347-21","volume":"12","author":"JM White","year":"2021","unstructured":"White JM et al (2021) Drug combinations as a first line of defense against coronaviruses and other emerging viruses. MBio 12(6):e0334721","journal-title":"MBio"},{"issue":"4","key":"4635_CR47","doi-asserted-by":"publisher","first-page":"104112","DOI":"10.1016\/j.isci.2022.104112","volume":"25","author":"A Ianevski","year":"2022","unstructured":"Ianevski A et al (2022) Mono- and combinational drug therapies for global viral pandemic preparedness. iScience 25(4):104112","journal-title":"iScience"},{"issue":"1","key":"4635_CR48","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41392-021-00653-w","volume":"6","author":"Q Zhang","year":"2021","unstructured":"Zhang Q et al (2021) Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduct Target Ther 6(1):233","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4635_CR49","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1038\/s41467-021-25361-5","volume":"12","author":"D Kim","year":"2021","unstructured":"Kim D et al (2021) A high-resolution temporal atlas of the SARS-CoV-2 translatome and transcriptome. Nat Commun 12(1):5120","journal-title":"Nat Commun"},{"issue":"5","key":"4635_CR50","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJMc2207519","volume":"387","author":"E Takashita","year":"2022","unstructured":"Takashita E et al (2022) Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med 387(5):468\u2013470","journal-title":"N Engl J Med"},{"issue":"5","key":"4635_CR51","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03331-22","volume":"10","author":"J Wagoner","year":"2022","unstructured":"Wagoner J et al (2022) Combinations of host- and virus-targeting antiviral drugs confer synergistic suppression of SARS-CoV-2. Microbiol Spectr 10(5):e0333122","journal-title":"Microbiol Spectr"},{"issue":"1","key":"4635_CR52","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s42003-022-03101-9","volume":"5","author":"X Wang","year":"2022","unstructured":"Wang X et al (2022) Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture. Commun Biol 5(1):154","journal-title":"Commun Biol"},{"issue":"9","key":"4635_CR53","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3390\/v13091768","volume":"13","author":"A Ianevski","year":"2021","unstructured":"Ianevski A et al (2021) Nafamostat-interferon-alpha combination suppresses SARS-CoV-2 infection in vitro and in vivo by cooperatively targeting host TMPRSS2. Viruses 13(9):1768","journal-title":"Viruses"},{"issue":"12","key":"4635_CR54","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.3390\/v13122489","volume":"13","author":"A Ianevski","year":"2021","unstructured":"Ianevski A et al (2021) Synergistic interferon-alpha-based combinations for treatment of SARS-CoV-2 and other viral infections. Viruses 13(12):2489","journal-title":"Viruses"},{"issue":"6515","key":"4635_CR55","doi-asserted-by":"publisher","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","volume":"370","author":"P Bastard","year":"2020","unstructured":"Bastard P et al (2020) Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370(6515):eabd4585","journal-title":"Science"},{"key":"4635_CR56","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.coi.2022.01.003","volume":"74","author":"P Bastard","year":"2022","unstructured":"Bastard P et al (2022) Type I interferons and SARS-CoV-2: from cells to organisms. Curr Opin Immunol 74:172\u2013182","journal-title":"Curr Opin Immunol"},{"issue":"22","key":"4635_CR57","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher A et al (2021) Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 384(22):2092\u20132101","journal-title":"N Engl J Med"},{"key":"4635_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102683","volume":"122","author":"AI Rodriguez-Perez","year":"2021","unstructured":"Rodriguez-Perez AI et al (2021) Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. J Autoimmun 122:102683","journal-title":"J Autoimmun"},{"key":"4635_CR59","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.antiviral.2018.05.005","volume":"155","author":"S Chaudhuri","year":"2018","unstructured":"Chaudhuri S, Symons JA, Deval J (2018) Innovation and trends in the development and approval of antiviral medicines: 1987\u20132017 and beyond. Antiviral Res 155:76\u201388","journal-title":"Antiviral Res"},{"issue":"3","key":"4635_CR60","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1128\/CMR.00102-15","volume":"29","author":"E De Clercq","year":"2016","unstructured":"De Clercq E, Li G (2016) Approved antiviral drugs over the past 50 years. Clin Microbiol Rev 29(3):695\u2013747","journal-title":"Clin Microbiol Rev"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-022-04635-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-022-04635-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-022-04635-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T04:40:25Z","timestamp":1670992825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-022-04635-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,27]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4635"],"URL":"https:\/\/doi.org\/10.1007\/s00018-022-04635-1","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,27]]},"assertion":[{"value":"22 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"605"}}